News & Updates
Showing Multidisciplinary articles
Showing

INHALE-3 underpins alternate insulin delivery method for T1D
Findings from the phase IV INHALE-3 trial support inhaled insulin for the management of type 1 diabetes (T1D) in adults, underlining its role as an alternative insulin solution to enhance diabetes management.

Automated insulin delivery system beneficial for T2D management
An automated insulin delivery (AID) system appears to improve clinical outcomes in people with type 2 diabetes (T2D), with the pivotal SECURE-T2D trial showing substantial improvements in glycated haemoglobin, total daily insulin dose, and diabetes distress, without increasing the risk of hypoglycaemia.

Pemvidutide gains MOMENTUM in phase II obesity trial
Pemvidutide, an investigational, peptide-based GLP-1/glucagon dual receptor agonist, gains traction in the booming obesity drug market, delivering significant weight loss reductions in nondiabetic individuals with overweight or obesity in the phase II MOMENTUM trial.





